If so, please submit the following information to participate in the class action:
Abington Cole + Ellery is investigating reports that certain Allergan BIOCELL tissue expanders and breast implants may cause anaplastic large cell lymphoma ("BIA-ALCL"), an immune system cancer.
On July 24, 2019, the United States Food and Drug Administration, otherwise known as the FDA, requested that BIOCELL textured tissue expanders and breast implants manufactured, marketed, and sold by Allergan be recalled from the US market. The agency reports this was to protect patients from the heightened danger of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), linked with Allergan’s BIOCELL textured tissue expanders and breast implants. The FDA's request for recall is supported by a stated global aggregate of 573 individual BIA-ALCL incidents. (This included 33 patient mortalities as of July 24, 2019.) Of the global aggregate of 573 incidents of BIA-ALCL, 84% (481 of 573) of the affected individuals were stated to have had Allergan tissue expanders or breast implants when the BIA-ALCL was found.
The textured tissue expanders and breast implants BIA-AICL recalled by Allergan include the following types of expanders and implants:
***** Allergan Natrelle 410 Highly Cohesive Anatomically Shaped Silicone Filled Breast Implants approved under P040046.
***** Allergan Natrelle Silicone-Filled Textured Breast Implants (formerly called Silicone-Filled Breast Implants) approved under P020056.
***** Allergan Natrelle Saline-Filled Breast Implants (formerly called McGhan RTV Saline-Filled Mammary Implant) approved under P990074.
An FDA Safety Communication provides additional information about the exact style names included in the recall and the FDA's recommendation for individuals with a recalled implant.
The FDA Safety Communication states that recently presented Medical Device Reports (also known as MDRs) show incidents of BIA-ALCL and BIA-ALCL-linked fatalities linked with these types of tissue expanders and breast implants worldwide. Of the 33 reported mortalities, 92% (12 of 13) of the mortalities occurring in individuals diagnosed with BIA-ALCL where the implant maker was identified occurred in individuals with an Allergan tissue expander or breast implant when the individual was diagnosed with BIA-ALCL. As for the other 20 BIA-ALCL reported mortalities, the texture and/or manufacturer was not known or reported.
If you or a loved one were implanted with an Allergan tissue expander or breast implant and were later diagnosed with BIA-ALCL and would like to learn more about participating in a class action lawsuit, please submit your information via the form on this webpage.
This website is not associated with nor authorized by Allergan or any affiliated companies.